long intergenic non-protein coding RNA 1812Genealiases: []
Q-omics provides the consensus-scored LINC01812 profile across patient tissues and cancer cell-line models. LINC01812 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01812 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LINC01812 RNA expression shows 7,748 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRP, KIRC, and LIHC as cancer lineages where LINC01812 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01812 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01812 survival associations across molecular data types. LINC01812 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01812 RNA expression–survival associations across cancer types. High LINC01812 expression shows unfavorable associations in KIRP, UVM, LIHC, HNSC and ACC, but favorable associations in CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01812 RNA expression.
This table summarizes LINC01812 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01812. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01812 shows lower tumor expression in KIRC, BRCA and KICH and higher tumor expression in LUAD, THCA and LUSC. The KIRC box plot shows higher LINC01812 RNA expression in normal versus tumor tissue (log2 FC = −0.115, t-test p = .005).
This table shows molecular features associated with LINC01812 in patient tissues and cancer cell lines. In patient samples, LINC01812 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
